Startup profile · funding coverage
Pathos AI funding, valuation and investors
AI drug-development company using its Foundry platform to select clinical assets and guide its own therapeutic pipeline.
Keep track of Pathos AI
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series E
$237M · October 23, 2026
Latest known valuation
Approximately $3B post-money
Series E · October 23, 2026
Total disclosed equity funding
$664M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · New York City, United States
Investors in latest funding
Lead: Bristol Myers Squibb
Other: Unnamed existing investors
Overview
Pathos AI is a New York City clinical-stage AI and technology company developing drugs. Its Foundry platform combines clinical, genomic and other evidence to support asset selection and trial-development decisions. Pathos also licenses and advances therapeutic programs. Platform-performance and clinical-success improvements remain company claims.
Why Pathos AI is interesting
Bristol Myers Squibb led Pathos's $237M Series E, announced October 23, 2026 at an approximately $3B post-money valuation, while entering a platform partnership. A separate Tempus agreement provides neurological data for fees of up to $55M over five years; these payments are not financing into Pathos.
Product & use cases
Foundry is intended to update evidence and probability-of-success assessments across drug programs. Pathos owns or licenses clinical assets and also provides pharmaceutical partners access to its platform. BMS access pricing was undisclosed in the October 23 announcements.
Key facts
- October 23, 2026: closed $237M Series E led by Bristol Myers Squibb.
- Approximately $3B post-money valuation disclosed by the company.
- JSKN016 was developed by Alphamab and licensed by Pathos; it was not invented by Pathos's AI.
- Funding history lists individually documented Series C, D and E rounds. The company reported $102M cumulative funding in October 2024; earlier financing was not itemized in that announcement.
Funding history (newest first)
Series E
2026-10-23 $237M Valuation: Approximately $3B post-money- Bristol Myers Squibb (lead)
- Unnamed existing investors (participant)
Source: Read source · pathos.com
Series D
2025-05-15 $365M Valuation: Approximately $1.6B post-moneySource: Read source · pathos.com
Series C
2024-10-29 $62M Valuation: $600M post-money- New Enterprise Associates (NEA) (lead)
- Revolution Growth (participant)
- Lightbank (participant)
- Builders VC (participant)
Source: Read source · pathos.com
Investors in our directory
Funds linked from Pathos AI's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
-
Isomorphic Labs adjacent
AI drug design and therapeutic-program development; discovery-focused model differs from Pathos's clinical-asset selection and development.
-
Insilico Medicine adjacent
AI drug discovery platform and proprietary pipeline; relevant R&D comparison, not an identical workflow.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Pathos AI's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.